IN2014DN06781A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN06781A IN2014DN06781A IN6781DEN2014A IN2014DN06781A IN 2014DN06781 A IN2014DN06781 A IN 2014DN06781A IN 6781DEN2014 A IN6781DEN2014 A IN 6781DEN2014A IN 2014DN06781 A IN2014DN06781 A IN 2014DN06781A
- Authority
- IN
- India
- Prior art keywords
- salt
- salts
- cushing
- aromatase
- pyrrolo
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 108010078554 Aromatase Proteins 0.000 abstract 1
- 102000014654 Aromatase Human genes 0.000 abstract 1
- 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 abstract 1
- 102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- -1 imidazol 5 yl 3 fluoro benzonitrile Chemical compound 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 150000002823 nitrates Chemical class 0.000 abstract 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261587280P | 2012-01-17 | 2012-01-17 | |
| PCT/US2013/021521 WO2013109514A1 (en) | 2012-01-17 | 2013-01-15 | New forms and salts of a dihydropyrrolo[1,2-c]imidazolyl aldosterone synthase or aromatase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN06781A true IN2014DN06781A (enrdf_load_html_response) | 2015-05-22 |
Family
ID=47604250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN6781DEN2014 IN2014DN06781A (enrdf_load_html_response) | 2012-01-17 | 2013-01-15 |
Country Status (40)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG182393A1 (en) * | 2010-01-14 | 2012-08-30 | Novartis Ag | Use of an adrenal hormone-modifying agent |
| EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| PE20170201A1 (es) * | 2014-07-07 | 2017-04-08 | Novartis Ag | Formas de dosificacion farmaceutica |
| EP3250555B1 (en) * | 2015-01-29 | 2021-03-03 | Recordati AG | Process for the production of condensed imidazolo derivatives |
| US20160287565A1 (en) * | 2015-04-06 | 2016-10-06 | Millendo Therapeutics, Inc. | Combination therapy for treating disorders associated with excess cortisol production |
| KR20230037680A (ko) * | 2016-10-27 | 2023-03-16 | 다미안 파르마 에이쥐 | 알도스테론 합성효소 저해제 |
| WO2018078049A1 (en) * | 2016-10-27 | 2018-05-03 | Damian Pharma Ag | Aldosterone synthase inhibitor |
| EP3787623A1 (en) | 2018-05-03 | 2021-03-10 | Damian Pharma AG | R-fadrozole for use in the treatment of aldostonerism |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1315449A (en) * | 1918-11-15 | 1919-09-09 | Frank B Yingling | Shaper-feed. |
| US4617307A (en) | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
| US5066656A (en) | 1989-11-01 | 1991-11-19 | Janssen Pharmaceutica N.V. | Pharmacologically active (6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivatives |
| MTP1076B (en) * | 1990-01-12 | 1991-09-30 | Ciba Geigy Ag | Hemihydrate |
| HU222117B1 (hu) | 1992-01-27 | 2003-04-28 | Janssen Pharmaceutica N.V. | Pirrolo[1,2-c] imidazolil- és imidazo[1,5-a] piridil-csoporttal szubsztituált 1H-benzimidazol-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyászati készítmények |
| EP1565463B1 (en) * | 2002-11-18 | 2008-06-11 | Novartis AG | Imidazo[1,5a] pyridine derivatives and methods for treating aldosterone mediated diseases |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| JP2010513560A (ja) | 2006-12-18 | 2010-04-30 | ノバルティス アーゲー | １−置換イミダゾール誘導体およびアルドステロン合成阻害剤としてのその使用 |
| WO2011064376A1 (en) | 2009-11-30 | 2011-06-03 | Novartis Ag | Imidazole derivatives as aldosterone synthase inhibitors |
| SG182393A1 (en) * | 2010-01-14 | 2012-08-30 | Novartis Ag | Use of an adrenal hormone-modifying agent |
-
2013
- 2013-01-15 IN IN6781DEN2014 patent/IN2014DN06781A/en unknown
- 2013-01-15 TW TW102101537A patent/TWI609869B/zh not_active IP Right Cessation
- 2013-01-15 DK DK13701194.6T patent/DK2804863T3/en active
- 2013-01-15 EP EP13701194.6A patent/EP2804863B1/en active Active
- 2013-01-15 JP JP2014552375A patent/JP5749410B2/ja active Active
- 2013-01-15 PE PE2014001112A patent/PE20142358A1/es not_active Application Discontinuation
- 2013-01-15 KR KR20147030158A patent/KR20140141687A/ko not_active Ceased
- 2013-01-15 UA UAA201406492A patent/UA114803C2/uk unknown
- 2013-01-15 JO JOP/2013/0014A patent/JO3137B1/ar active
- 2013-01-15 RS RS20160109A patent/RS54589B1/en unknown
- 2013-01-15 SI SI201330142A patent/SI2804863T1/sl unknown
- 2013-01-15 US US14/370,124 patent/US9334276B2/en active Active
- 2013-01-15 BR BR112014017260A patent/BR112014017260A8/pt not_active Application Discontinuation
- 2013-01-15 AU AU2013209952A patent/AU2013209952B2/en active Active
- 2013-01-15 KR KR1020147016954A patent/KR20140093726A/ko not_active Ceased
- 2013-01-15 MX MX2014008686A patent/MX2014008686A/es unknown
- 2013-01-15 CA CA2863339A patent/CA2863339C/en active Active
- 2013-01-15 SG SG11201404061YA patent/SG11201404061YA/en unknown
- 2013-01-15 NZ NZ626277A patent/NZ626277A/en not_active IP Right Cessation
- 2013-01-15 ES ES13701194.6T patent/ES2564143T3/es active Active
- 2013-01-15 WO PCT/US2013/021521 patent/WO2013109514A1/en active Application Filing
- 2013-01-15 PL PL13701194T patent/PL2804863T3/pl unknown
- 2013-01-15 UY UY0001034576A patent/UY34576A/es not_active Application Discontinuation
- 2013-01-15 AP AP2014007762A patent/AP2014007762A0/xx unknown
- 2013-01-15 CN CN201380005054.0A patent/CN104039793B/zh active Active
- 2013-01-15 HU HUE13701194A patent/HUE026984T2/en unknown
- 2013-01-15 AR ARP130100119A patent/AR089728A1/es unknown
- 2013-01-15 EA EA201491374A patent/EA026232B1/ru not_active IP Right Cessation
- 2013-01-15 HR HRP20160178T patent/HRP20160178T1/hr unknown
-
2014
- 2014-06-11 ZA ZA2014/04314A patent/ZA201404314B/en unknown
- 2014-06-12 TN TNP2014000256A patent/TN2014000256A1/en unknown
- 2014-07-07 IL IL233541A patent/IL233541B/en active IP Right Grant
- 2014-07-08 CO CO14146898A patent/CO7000775A2/es unknown
- 2014-07-11 MA MA37199A patent/MA35858B1/fr unknown
- 2014-07-15 CL CL2014001863A patent/CL2014001863A1/es unknown
- 2014-07-15 CU CU2014000086A patent/CU20140086A7/es unknown
- 2014-07-17 CR CR20140345A patent/CR20140345A/es unknown
- 2014-07-17 GT GT201400155A patent/GT201400155A/es unknown
- 2014-07-17 PH PH12014501638A patent/PH12014501638A1/en unknown
-
2016
- 2016-02-09 US US15/018,953 patent/US20160176883A1/en not_active Abandoned
- 2016-02-26 CY CY20161100163T patent/CY1117914T1/el unknown
- 2016-03-23 SM SM201600083T patent/SMT201600083B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN06781A (enrdf_load_html_response) | ||
| IL290905A (en) | Crystal form of (s)–n-(5–)–2–(r))5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-a]pyrimidine-3-yl)-3 -Hydroxypyrrolidine-1-carboxamide hydrogen sulfate | |
| IL235659A0 (en) | History of 3, 4 - dihydro -2h - pyrido [1, 2 - a] pyrazine - 1,2,1] 6 converted diones used to treat (among others) Alzheimer's disease | |
| PH12013500872A1 (en) | Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof | |
| IN2014DN07384A (enrdf_load_html_response) | ||
| RS61319B1 (sr) | Pirazolo[1,5-a]pirimidini korisni kao inhibitori atr kinaze za lečenje kancera | |
| MX347917B (es) | Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso. | |
| GEP20156285B (en) | Compounds and compositions as trk inhibitors | |
| HRP20182007T1 (hr) | Derivati 3-okso-2,3,5,8-tetrahidro-[1,2,4]triazolo[4,3-a]pirimidina za liječenje respiratornih bolesti | |
| HK1216425A1 (zh) | 基於2，3-二氢咪唑并[1，2-c]嘧啶-5(1h)-酮的脂蛋白相关磷脂酶a2(lp-pla2)抑制剂 | |
| MX336332B (es) | Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia. | |
| TN2013000377A1 (en) | Thieno [2, 3-d] pyrimidine derivatives and their use to treat arrhythmia | |
| TN2013000483A1 (en) | Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives | |
| MX384986B (es) | Sal y formas polimorficas de (3r,4s)-l-((4-amino-5h-pirrolo[3,2-d]pirimidin-7-il)metil)-4(metiltiometil)pirodin-3-ol(mtdia). | |
| TN2013000146A1 (en) | Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof | |
| HK1173146A (en) | Kinase inhibitors, prodrug forms thereof and their use in therapy |